{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 41,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "Includes definitions for COPD, nOH, and PTE in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/34",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.13,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "COPD, Chronic obstructive pulmonary disease; nOH, neurogenic orthostatic hypotension; PTE, patent term extensions.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c257621-373c-4dd7-b2ee-1a851a4b4967",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.84,
        "x": 0.08,
        "y": 0.21
      },
      "kind": "table",
      "text": "Compound, Invention, Granted / Pending Application, Estimated Patent Expiry; YUPELRI / revefenacin, Composition of Matter, Granted US, 2028 (once PTE awarded); Polymorph, Granted US, 2030-2031; Method for the maintenance treatment of COPD patients, Granted US, 2039; Ampreloxetine, Composition of Matter, Granted US, 2030 (plus PTE of up to 5 years); Method of Treating nOH, Granted US, 2037",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12154054-6632-4b2d-bc55-51f4f2fdf081",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Patent Protection Into Late 2030s",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04bcf220-3918-485d-bc1b-bce07e94e33a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 5,
      "beatId": "18f97180-6c3c-4b05-a378-979222504b06",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Before-After",
      "beatSlug": null,
      "evidence": "Multiple slides show progress and growth using before-after comparisons.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}